Skip to content Skip to footer
Subscribe Now
Insights+ Key Biosimilars Events of November 2019
INSIGHTS+
Insights+ Key Biosimilars Events of November 2019
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' possessing similar…
December 6, 20190Comments
Biosimilar Companies Top 20 2018
TOP 20
Top Biosimilar Companies with Approved and Pipeline Products in the US and EU
​ Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases. Hence physicians are likely to adopt biosimilars a reference product to biologics possessing similar therapeutic properties in terms of potency- safety- and efficacy to original biologic products. The companies are focusing…
November 29, 20190Comments
Octavus Consulting Collaborates with IBCI for Delivering of Professional Educational Programs in India from 2020
INSIGHTS+
Octavus Consulting Collaborates with IBCI for Delivering of Professional Educational Programs in India from 2020
Shots: The IBCI educational programs will focus on providing perspectives on Business & Competitive Intelligence role in every industry for professionals from all domains in India. Additionally, IBCI has already provided 50 types of programs for 7000+ highly qualified professionals from every domain Octavus Consulting with its team expertise in Competitive Intelligence and Product Strategies…
November 28, 20190Comments
PharmaShots Interview: AstraZeneca's Global Medicine Leader John Houghton Shares Insights on Roxadustat in Treating Patients with Anemia Due to CKD at ASN 2019
VIEWPOINTS
PharmaShots Interview: AstraZeneca’s Global Medicine Leader John Houghton Shares Insights on Roxadustat in Treating Patients with Anemia Due to CKD at ASN 2019
AstraZeneca presented P-III data of Roxadustat along with unprecedented 41 abstracts from its renal portfolio at American Society of Nephrology Kidney Week 2019, demonstrating its commitment to advancing the care of Chronic Kidney Diseases (CKD) and its complications, affecting millions of people across the globe. On Nov 12, 2019 in an interview with PharmaShots, John…
November 12, 20190Comments
Insights+ Key Biosimilars Events of October 2019
INSIGHTS+
Insights+ Key Biosimilars Events of October 2019
Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars 'a reference product to biologics'possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the biosimilar…
November 1, 20190Comments

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]